Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/21/2025

Management of Chronic Obstructive Pulmonary Disease Exacerbations

Diagnosis and Evaluation

  • The European Respiratory Society suggests evaluating for key symptoms of exacerbation, including increased dyspnea, increased sputum volume, increased sputum purulence, increased wheeze, chest tightness, and fluid retention, and ruling out important differential diagnoses, such as pneumonia, pneumothorax, left ventricular failure/pulmonary edema, pulmonary embolus, lung cancer, and upper airway obstruction 1
  • Arterial blood gas measurement should be obtained to diagnose and quantify the severity of acute hypercapnic respiratory failure, as recommended by the British Thoracic Society 2, 3
  • A chest radiograph should be obtained to identify causative factors or complications, but should not delay non-invasive ventilation (NIV) if pH <7.25, according to the British Thoracic Society 2, 1
  • Basic laboratory tests, including complete blood count, electrolytes, and ECG, should be performed, as suggested by the British Thoracic Society 1
  • Sputum culture should be obtained if purulent sputum is present, as recommended by the British Thoracic Society 1

Treatment of Exacerbations

  • Salbutamol should be administered to COPD patients experiencing an exacerbation, regardless of wheezing presence, as bronchodilators are indicated for all COPD exacerbations based on severity, according to the European Respiratory Society 4, 5
  • Systemic corticosteroids are recommended as the primary treatment for COPD exacerbations to reduce the risk of treatment failure and relapse, with a typical dose of prednisone 30-40mg daily for 5 days, according to the American College of Chest Physicians 6
  • Controlled oxygen therapy with a target saturation of 88-92% should be used to prevent worsening respiratory acidosis, according to the British Thoracic Society 2, 3, 7, 8
  • NIV should be initiated if pH <7.35 and pCO₂ >6.5 kPa persist despite optimal medical therapy, as recommended by the British Thoracic Society 2
  • The following treatment requirements are recommended based on exacerbation severity:
Exacerbation Severity Treatment Requirements
Mild Outpatient treatment, bronchodilators, and possibly oral corticosteroids
Moderate Hospitalization or emergency room visit, bronchodilators, oral corticosteroids, and possibly antibiotics
Severe Hospitalization or emergency room visit, bronchodilators, oral corticosteroids, antibiotics, and possibly noninvasive ventilation [9]

Prevention of Exacerbations

  • COPD exacerbations can be prevented through smoking cessation, vaccination (influenza, pneumococcal), appropriate maintenance therapy, pulmonary rehabilitation, and early recognition and treatment of exacerbations, with consideration of prophylactic macrolide therapy, such as azithromycin 250 mg daily or 500 mg three times weekly, to reduce exacerbation rates in patients with moderate to severe COPD who have had one or more exacerbations in the previous year despite optimal maintenance inhaler therapy, as recommended by the American Thoracic Society 9, 10, 11, 6, 9
  • Regular airway clearance techniques, influenza and pneumococcal vaccination, and consideration of periodic sputum cultures to monitor colonizing organisms should be used for patients with chronic bronchiectasis, previous lung surgery, recent antibiotic exposure, and failed outpatient therapy to prevent future exacerbations, as recommended by the American Thoracic Society 12

Follow-up and Discharge

  • Patients should be monitored carefully for developing hypercapnic respiratory failure, even if initial blood gases were satisfactory, as recommended by the British Thoracic Society 3
  • Maintenance therapy with long-acting bronchodilators should be initiated before hospital discharge to prevent subsequent exacerbations, ensure proper inhaler technique, and schedule follow-up within 1-2 weeks after discharge, as recommended by the American Thoracic Society 9
  • Pulmonary rehabilitation should be started within 3 weeks after hospital discharge, and follow-up timing should be within 48 hours for mild exacerbations and within 1-2 weeks after discharge for moderate exacerbations, with monitoring for worsening symptoms, decreasing oxygen saturation, altered mental status, and inability to maintain oral intake, as recommended by the American Thoracic Society 10, 13, 9, 1, 12
  • Discharge criteria include sustained response to bronchodilators, ability to use inhalers correctly, PEF or FEV1 >70% of predicted or personal best, and oxygen saturation >90% on room air, as recommended by the American Thoracic Society 14

REFERENCES